Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer

Clinical Pharmacokinetics
Tessa M BoschJan H M Schellens

Abstract

There is wide variability in the response of individuals to standard doses of drug therapy. This is an important problem in clinical practice, where it can lead to therapeutic failures or adverse drug reactions. Polymorphisms in genes coding for metabolising enzymes and drug transporters can affect drug efficacy and toxicity. Pharmacogenetics aims to identify individuals predisposed to a high risk of toxicity and low response from standard doses of anti-cancer drugs. This review focuses on the clinical significance of polymorphisms in drug-metabolising enzymes (cytochrome P450 [CYP] 2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, dihydropyrimidine dehydrogenase, uridine diphosphate glucuronosyltransferase [UGT] 1A1, glutathione S-transferase, sulfotransferase [SULT] 1A1, N-acetyltransferase [NAT], thiopurine methyltransferase [TPMT]) and drug transporters (P-glycoprotein [multidrug resistance 1], multidrug resistance protein 2 [MRP2], breast cancer resistance protein [BCRP]) in influencing efficacy and toxicity of chemotherapy. The most important example to demonstrate the influence of pharmacogenetics on anti-cancer therapy is TPMT. A decreased activity of TPMT, caused by genetic polymorphisms in the TPMT gene, causes severe tox...Continue Reading

References

Jan 1, 1989·Pharmacology & Therapeutics·D A Evans
Feb 24, 1998·British Journal of Cancer·S A RidgeH L McLeod
Jan 28, 1999·Biochemical and Biophysical Research Communications·U YasarF Sjöqvist
May 20, 1999·Annual Review of Pharmacology and Toxicology·S V AmbudkarM M Gottesman
Oct 27, 2001·British Journal of Clinical Pharmacology·J A Goldstein
May 7, 2002·The Pharmacogenomics Journal·N J ButcherR F Minchin
Jan 25, 2003·Annals of Clinical Biochemistry·André B P van KuilenburgAlbert H van Gennip
Jul 25, 2003·European Journal of Clinical Pharmacology·Elena A GaikovitchIvar Roots
Apr 9, 2005·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Tessa M BoschIrma Meijerman
Dec 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew P GoetzJames N Ingle

❮ Previous
Next ❯

Citations

Jan 6, 2007·Cancer Chemotherapy and Pharmacology·S A VeltkampJ H M Schellens
Aug 13, 2009·Cancer Chemotherapy and Pharmacology·Judith Meza-JuncoMichael B Sawyer
Aug 5, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ya-Hsu YangHao-Wei Teng
May 8, 2007·Investigational New Drugs·Gene L BidwellDrazen Raucher
Oct 9, 2007·Investigational New Drugs·Qi-Biao SuShu-Feng Zhou
Jul 8, 2008·Evidence-based Complementary and Alternative Medicine : ECAM·Ying LiuMasuro Motoi
Nov 8, 2008·Journal of Pediatric Hematology/oncology·Marie Louise DavidsenKjeld Schmiegelow
Jan 5, 2012·Journal of Pediatric Hematology/oncology·Louise BorstKjeld Schmiegelow
Sep 27, 2006·Molecular Neurodegeneration·Suzanne V FrankfortJos H Beijnen
Jun 13, 2008·BMC Medical Genomics·Zunyan DaiWolfgang Sadee
Dec 14, 2012·PloS One·Saskia PreissnerKarlheinz Seeger
Sep 21, 2011·Neuropsychiatric Disease and Treatment·Nancy K GillisJohn S Markowitz
Jan 3, 2012·Advances in Nutrition·Sarah Egert, Gerald Rimbach
Jul 19, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Jun-Ichi YamakawaJunji Kobayashi
Dec 12, 2013·Breast Cancer Research : BCR·Olivier HarismendyKelly A Frazer
Oct 11, 2007·Pharmacogenomics·Christine M Hartford, M Eileen Dolan
Sep 20, 2006·Pharmacogenomics·Rashmi R Shah
Dec 24, 2009·QJM : Monthly Journal of the Association of Physicians·O Jolobe
Sep 19, 2008·Expert Opinion on Drug Metabolism & Toxicology·Bo GaoHoward Gurney
Sep 30, 2008·Drug Metabolism Reviews·Young-Mi AhSang Geon Kim
Apr 1, 2009·Expert Opinion on Drug Metabolism & Toxicology·Viet Hong PhanStephen J Clarke
Sep 29, 2011·Expert Opinion on Drug Metabolism & Toxicology·Viet Hong PhanStephen J Clarke
Nov 22, 2007·Expert Opinion on Drug Metabolism & Toxicology·Michael Michael, Margaret M Doherty
Mar 29, 2008·Expert Opinion on Drug Metabolism & Toxicology·Rainer Cermak
Apr 3, 2008·Journal of Pharmaceutical Sciences·Shiori TakahashiTsuyoshi Yokoi
Sep 17, 2013·Translational Research : the Journal of Laboratory and Clinical Medicine·Azza A K El-SheikhFrans G M Russel
Jan 25, 2011·Seminars in Oncology Nursing·Cynthia A Prows
Jan 13, 2009·Advanced Drug Delivery Reviews·Toshiyuki SakaedaKohshi Nishiguchi
Jun 7, 2008·Pathology, Research and Practice·Neel SenguptaAndrew Silver
Dec 19, 2006·Mutation Research·R K Elespuru, K Sankaranarayanan
Jun 6, 2008·Journal of Clinical Pharmacology·J Andrew WilliamsSteven A Wrighton

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.